Mode of action of DNA-competitive small molecule inhibitors of tyrosyl DNA phosphodiesterase 2

Peter Hornyak*†, Trevor Askwith‡, Sarah Walker‡, Emilia Komulainen*, Michael Paradowski‡, Lewis E. Pennicott‡, Edward J. Bartlett*†, Nigel C. Brissett*, Ali Raoof§, Mandy Watson§, Allan M. Jordan§, Donald J. Ogilvie§, Simon E. Ward‡, John R. Atack‡, Laurence H. Pearl†‡, Keith W. Caldecott*‡ and Antony W. Oliver†‡

*Genome Damage and Stability Centre, School of Life Sciences, University of Sussex, Falmer BN1 9RQ, U.K.
†Cancer Research UK DNA Repair Enzymes Group, Genome Damage and Stability Centre, School of Life Sciences, University of Sussex, Falmer BN1 9RQ, U.K.
‡Sussex Drug Discovery Centre, School of Life Sciences, University of Sussex, Falmer BN1 9QJ, U.K.
§Drug Discovery Unit, Cancer Research UK Manchester Institute, University of Manchester, Manchester M20 4BX, U.K.

Tyrosyl-DNA phosphodiesterase 2 (TDP2) is a 5′-tyrosyl DNA phosphodiesterase important for the repair of DNA adducts generated by non-productive (abortive) activity of topoisomerase II (TOP2). TDP2 facilitates therapeutic resistance to topoisomerase poisons, which are widely used in the treatment of a range of cancer types. Consequently, TDP2 is an interesting target for the development of small molecule inhibitors that could restore sensitivity to topoisomerase-directed therapies. Previous studies identified a class of deazaflavin-based molecules that showed inhibitory activity against TDP2 at therapeutically useful concentrations, but their mode of action was uncertain. We have confirmed that the deazaflavin series inhibits TDP2 enzyme activity in a fluorescence-based assay, suitable for high-throughput screen (HTS)-screening. We have gone on to determine crystal structures of these compounds bound to a ‘humanized’ form of murine TDP2. The structures reveal their novel mode of action as competitive ligands for the binding site of an incoming DNA substrate, and point the way to generating novel and potent inhibitors of TDP2.

Key words: deoxyribonucleic acid (DNA) synthesis and repair, drug discovery and design, topoisomerase.

INTRODUCTION

Tyrosyl-DNA phosphodiesterase 2 (TDP2) [also known as TRAF and TNF receptor-associated gene (TTRAP) [1] or ETS1-associated protein II (EAPII) [2]] is a 5′-tyrosyl DNA phosphodiesterase that can remove the covalently-attached abortive complexes generated by DNA topoisomerase II (TOP2) when it is unable to complete its normal catalytic cycle [3,4]. TDP2 has also been co-opted by picornaviruses as the ‘unlinkase’ that releases nascent RNA from its VPg protein primer during viral replication [5].

TDP2 generates transient double-strand breaks (DSBs) in genomic DNA that relieve torsional stress introduced during transcription and replication [6]. The mechanism of DNA strand cleavage by TOP2 involves formation of a covalent reaction intermediate between the side chain of a catalytic tyrosine in the enzyme, and the 5′-phosphate at the site of the DNA-strand break. TDP2 functions as a dimer, and produces a staggered DSB, with the nicks in the two strands separated by 4 bp. Normally, following passage of a distal segment of duplex DNA through the break, TDP2 facilitates attack on the phosphotyrosyl bonds by the free 3′-OH at the nicks, resealing the break and releasing the enzyme. In some circumstances, TDP2 is unable to complete the reaction cycle, leaving it covalently attached to the DSB 5′-termini in a highly toxic, abortive, ‘cleavage complex’ that can severely disrupt replication and transcription. Fortunately, this type of DNA lesion is efficiently repaired, in part though the action of TDP2, which hydrolyses the phosphotyrosyl bond in a magnesium cofactor-dependent reaction, leaving ligatable 5′-phosphate moieties.

TOP2 ‘poisons’ such as doxorubicin (Adriamycin) are known to intercalate into DNA (PDB: 1D12; [7]); amssacrine (nAMSA) and etoposide (VP-1) have also been demonstrated to bind selectively at the nick sites of a TOP2–DNA complex (PDB: 4G0U, 3QX3; [8]) and prevent resealing of the strands. These interactions promote the cumulative formation of abortive TOP2–DNA complexes, leading ultimately to cell death in rapidly proliferating cells. Consequently, TOP2 poisons are potent anticancer agents [9], and are currently used in the clinic either as monotherapies, or as components of combination therapies for a range of tumour types [10–12]. However, the abortive complexes promoted by TOP2 poisons can be rescued by the action of TDP2, so that variations in cellular TOP2 activity (natural or tumour-specific) can influence the clinical efficacy of these drugs, and are therefore an important determinant of response to chemotherapy in the individual patient and tumour. Consequently, TDP2 has attracted interest as a target for small molecule inhibitors that might have utility in overcoming innate or acquired resistance to TOP2 poisons.

A series of potent TDP2 inhibitors based on a deazaflavin scaffold have previously been described, but their molecular mode of action could not be determined and the rational exploitation of...
structure–activity relationships (SARs) was consequently limited [13]. Using a ‘humanized’ mouse TDP2 expression construct, we have now determined X-ray crystal structures of the catalytic domain of TDP2 in complex with deazaflavin inhibitors, revealing the unusual molecular interactions underpinning their mode of action. These results provide a platform for structure-based drug design that will greatly assist the future development of small molecule inhibitors of human TDP2.

MATERIALS AND METHODS

Expression constructs

htDP2CAT

DNA encoding the catalytic domain of human TDP2 (amino acids 113–362) was cloned into pET-28a (Novagen, Merck Chemicals). Using standard site-directed mutagenesis techniques, a single-point mutant – C273S – was subsequently introduced into this expression construct; improving the behaviour of the recombinant protein, qualitatively with respect to both solubility and aggregation.

mtDP2CAT/m2hDP2CAT

Synthetic genes codon-optimized for Escherichia coli expression were sub-cloned into an in-house modified form of pET-15b, which encodes an N-terminal His-small ubiquitin-like modifier (SUMO) affinity/solubility tag that is cleavable by sentrin-specific protease 1 (SENP1) protease (Genscript). The mTDP2CAT expression construct encodes amino acids Leu118–Leu370 of the mTDP2CAT/m2hTDP2CAT strain: Rosetta 2(DE3)pLysS (Novagen); antibiotic selection: 50 μg/ml ampicillin/34 μg/ml chloramphenicol. The His-SUMO affinity/solubility tag was cleaved overnight at 4 °C by the addition of SENP1 protease, after the initial Talon capture step.

Protein expression and purification

htDP2CAT

Transformed colonies of E. coli strain B834 (DE3) were used to inoculate a 250 ml flask containing 50 ml of Turbo broth (Molecular Dimensions) supplemented with kanamycin (50 μg/ml). The inoculated culture was grown at 37 °C, at 220 rpm, in an orbital shaking incubator until the absorbance at 600 nm reached approximately 1.5. The culture was then stored overnight at 4 °C.

The following day, 20 ml of the overnight culture was used to inoculate a 2 litre flask containing 1 litre of Turbo broth supplemented with antibiotic as before. Cultures were grown at 37 °C, at 220 rpm, in an orbital shaking incubator until the absorbance at 600 nm again reached approximately 1.5. Recombinant protein expression was then induced by the addition of 0.4 mM IPTG, and the culture incubated for a further 3.5 h at a reduced temperature of 30 °C. Cells were then harvested by centrifugation at 7548 g, for 10 minutes at 4 °C, and the resulting cell pellet stored at −80 °C until required.

The cell pellet arising from 4 litres of culture was resuspended in buffer A: 50 mM HEPES/NaOH, pH 7.5, 250 mM NaCl, 10 mM imidazole, 0.5 mM TCEP, supplemented with protease inhibitors (Roche), then disrupted by sonication, and the resulting lysate clarified by high-speed centrifugation at 40000 g, for 60 min at 4 °C.

The supernatant was applied to a batch/gravity flow column containing 10 ml of Talon resin (TaKaRa Bio) pre-equilibrated in buffer A. After incubation (with rolling) for a period of 1 h at 4 °C, any unbound material was removed by sequential washes with buffer A. Retained protein was then eluted by application of the same buffer supplemented with 300 mM imidazole, pH 7.5.

The eluate was diluted, in order to reduce the salt concentration to <150 mM NaCl, and then applied to a 5 ml HiTrap Heparin HP column (GE Healthcare) equilibrated in buffer B: 50 mM HEPES/NaOH, pH 7.5, 150 mM NaCl, 1 mM TCEP. Unbound material was first removed by application of five column volumes of the same buffer. Any retained protein was eluted, through application of a linear salt gradient (0.15–1 M NaCl) to the column.

A HiLoad 16/600 Superdex 75 pg size exclusion column (GE Healthcare) was used to purify hTDP2-CAT to homogeneity in 20 mM HEPES/NaOH, pH 7.5, 300 mM NaCl, 0.5 mM TCEP.

mtDP2CAT/m2hDP2CAT

A similar protocol was also used to purify both mTDP2CAT and m2hTDP2CAT, with the following alterations: E. coli strain: Rosetta 2(DE3)pLysS (Novagen); antibiotic selection: 50 μg/ml ampicillin/34 μg/ml chloramphenicol. The His-SUMO affinity/solubility tag was cleaved overnight at 4 °C by the addition of SENP1 protease, after the initial Talon capture step.

Thermal denaturation

For thermal denaturation, samples containing protein at 1.7 μM and 5 x SYPRO Orange (diluted from a 5000 x stock supplied in DMSO; Sigma–Aldrich) were prepared in sample buffer: 50 mM HEPES/NaOH, pH 7.5, 300 mM NaCl, 0.5 mM TCEP. Either DMSO alone or compound [dissolved in 100 % (v/v) DMSO at its maximum solubility] was then added; producing a final concentration of 3 % (v/v) DMSO. Denaturation curves were monitored in 96-well PCR plates using a Roche LightCycler 480 II, with 465 nm and 580 nm filters for excitation and emission wavelengths respectively. The programme was as follows: 1 min at 20 °C, followed by a continuous increment of 0.03 °C/s to a final temperature of 85 °C. Temperature midpoints (Tm) for each folded transition were determined by non-linear regression fitting of a modified Boltzmann model to normalized data in Prism 6.0 (version 6.0h, GraphPad Software).

\[
Y = (a_n X + b_n) + \frac{(a_d X + b_d) - (a_n X + b_n)}{1 + e^{-\frac{T_m - X}{b_n}}}
\]

where \(a_n\) and \(a_d\) are the slopes and \(b_n\) and \(b_d\) the \(\gamma\)-intercepts, of the native and denatured baselines respectively. \(T_m\) is the temperature midpoint of the transition from native to denatured states and \(m\) represents a generic slope factor.

Fluorescence-based enzyme activity assay

Substrate oligonucleotide containing a 5'-phosphothreonine (5'-Y-GATCCTAAAGACT-3') conjugated to FITC was purchased from Midland Certified Reagents.

This assay is a modified version of that reported by [14]. Briefly, enzyme assays were run in black 384-well plates, in 50 mM Tris/HCl, pH 8.0, 10 mM MgCl2, 80 mM KCl, 0.05 % (v/v) Tween-20, 1 mM DTT. Fifty picomoles of hTDP2CAT were combined with 25 nM substrate oligonucleotide, in a final volume of 15 μl, for a period of 10 min, before addition of quench reagents (Gyrosol Technologies; sensor diluted 1:15 with enhancer buffer). Fluorescence was subsequently measured in a PHERaStar multimode plate reader (BMG Labtech GmbH) with
an excitation wavelength of 490 nm, and an emission wavelength of 520 nm. The built-in analysis tools of Prism 6.0 was used to examine all experimental data.

**Gel-based enzyme activity assay**

This assay is a modified version of that reported by [3,4]. Briefly, recombinant TDP2CAT proteins were diluted with reaction buffer: 50 mM Tris/HCl, pH 7.5, 50 mM KCl, 1 mM MgCl₂, 1 mM DTT to produce final concentrations of 1 nM (for hTDP2CAT and m2hTDP2CAT) or 3 nM (for mTDPM) in a volume of 16.2 μl – either in the presence or absence of compound [50 nM for hTDP2CAT and m2hTDP2CAT, 150 nM for mTDPM, 1% (v/v) final DMSO concentration]. To start the reaction, 1.8 μl of radiolabelled 5’-phosphotyrosyl DNA substrate was added to the mixture, then incubated at 37°C. At 2, 5 and 10 min time-points, 6 μl of the reaction mixture was withdrawn, and stopped by the addition of formamide loading buffer. Samples were then analysed by denaturing PAGE, visualized by phosphorimagor, with intensities of substrate and product bands measured by GelAnalyzer2010 software (http://www.gelanalyzer.com).

**Crystallization and data collection**

**hTDP2CAT**

Crystals of hTDP2CAT were grown at 20°C in 24-well hanging-drop vapour-diffusion plates, mixing 1 μl of protein at 7.5 mg/ml with 1 μl of 100 mM Bis–Tris propane, pH 7.0, 0.5 M NaCl, 0.05 M magnesium acetate, 1.5% (v/v) trimethylamine N-oxide, equilibrated against 500 μl of the same solution. Crystals were swiped successively through buffers containing increasing concentrations of cryo-protectant, before being plunged into liquid nitrogen; 30% (v/v) glycerol was sufficient to prevent ice formation.

Diffraction data to 3.1 Å (1 Å = 0.1 nm) resolution were collected at the Diamond Light Source (DLS) on beamline I04. Crystals grew in space group P3₁ 21, with two molecules of m2hTDP2CAT, both in complex with 163, comprising the asymmetric unit.

**m2hTDP2CAT/148**

Crystals of m2hTDP2CAT/148 were grown at 20°C in 24-well hanging-drop vapour-diffusion plates, mixing 1 μl of complex (1:2.7 molar ratio protein: compound) at approximately 7.5 mg/ml, with 1 μl of 0.1 M Bis–Tris propane pH 6.5, 0.2 M sodium tartrate, 20% (v/v) PEG3350, 0.3% (v/v) DMSO, equilibrated against 500 μl of the same solution. Crystals were swiped successively through buffers containing increasing concentrations of cryo-protectant, before being plunged into liquid nitrogen; 8% (v/v) glycerol + 5% (w/v) glucose was sufficient to prevent ice formation.

Diffraction data to 1.7 Å resolution were collected at the Diamond Light Source (DLS) on beamline I04. Crystals grew in space group P2₁, with two molecules of m2hTDP2CAT, both in complex with 148, comprising the asymmetric unit.

**Phasing, model building and refinement**

All diffraction data were collected at 100 K. Data were integrated using the software package XDS [15], and then processed using the Pointless/Aimless/Ctruncate pipeline of the CCP4 software suite [16–19]. Phases were obtained by molecular replacement, using PHASER with 4GYZ (mTDPM) as a search model [20]. An iterative combination of manual building in Coot [21] and refinement with either phenix.refine [22] or BUSTER [23] produced the final models.

**Compounds**

Compounds either were provided by the Cancer Research UK Manchester Institute Drug Discovery Unit or were re-synthesized in-house by LP or M.P., following the published protocols [13].

**RESULTS**

**Structure of the human TDP2 catalytic domain**

We obtained crystals of the catalytic domain of human TDP2 (Figure 1A; hTDP2CAT – residues 113–362), in its unliganded form, using protein expressed in E. coli and purified using standard chromatographic procedures (see ‘Materials and Methods’). The expression construct contains a single-point mutant – C273S – which removes a potentially reactive surface cysteine, and that in our hands significantly improved the expression levels and solubility of the recombinant protein.

The structure of hTDP2CAT was determined by molecular replacement, with the catalytic domain of mouse TDP2 as a search model (PDB: 4GYZ). However, crystals of hTDP2CAT typically diffracted both poorly and anisotropically. Through iterative screening of many crystals, we were eventually able to collect a dataset that could be truncated isotropically to a maximum resolution of 3.1 Å (see Table 1). The fold of the human protein is highly similar to that of mouse [24], worm [25],...
and zebrafish [25] (Figures 1B and 1C) but with some important differences – see expanded description below.

Deazaflavin inhibitors of TDP2

A series of small molecule deazaflavin inhibitors of human TDP2 have previously been described [13], with examples showing in vitro biochemical activity against the isolated enzyme in the nanomolar concentration range (Figure 2A). However, the precise mode of action of these compounds was unclear, and in the absence of an experimentally determined binding site, the SARs were difficult to rationalize.

As the original high-throughput screen (HTS) screens were performed with full-length human TDP2, we first sought to confirm binding of these compounds to hTDP2CAT by thermal denaturation [26]. Using the most potent reported deazaflavin – compound 163 [13], we observed a shift in the temperature midpoint ($T_m$) of hTDP2CAT from 48.7°C in the unliganded state, to 51.5°C in the presence of compound 163 at a concentration of 300 μM. These results are indicative of moderately tight binding of 163 to hTDP2CAT (Figure 2B).

We also confirmed inhibition of catalytic activity by three deazaflavin compounds, by using a modified form of a fluorescence-based assay [14]. A phosphotyrosyl moiety conjugated to FITC was readily removed from the 5′ end of a single-stranded oligonucleotide substrate by hTDP2CAT in a dose-dependent manner (Supplementary Figures S1A and S1B). We could subsequently determine $K_m$ for the oligonucleotide substrate (208 ± 23 nM), $K_{cat}$ for the reaction under the experimental conditions tested (1.58 ± 0.06 s⁻¹; Figure 2C), as well as IC₅₀ values for each of the deazaflavins; 163: 19, 148: 103, 149: 489 nM (Figure 2D). The IC₅₀ rank order is in agreement with the previously reported EC₅₀ values, which used full-length human TDP2 and BIOMOL Green as a detection/quantification agent [13].

Low-resolution co-crystal structure of hTDP2CAT bound to 163

As with the apo-hTDP2CAT crystals, co-crystals with 163 presented severe problems with anisotropy during data collection. Again, multiple crystals were screened before a dataset that could be truncated isotropically, to a maximum resolution of 3.4 Å, was obtained (Table 1). Despite the low-resolution, which prevents
Figure 2  Small molecule Inhibitors of human TDP2

(A) Chemical drawings of four deazaflavin-based inhibitors of human TDP2, as described by Raoof et al. [13]. Compound numbering and EC50 values are as previously reported. (B) Thermal denaturation profiles for hTDP2CAT in the absence or presence of 300 μM 163. The experimental data (data points coloured in black) were fitted with a modified Boltzmann model to obtain the indicated Tm for the apo- (red curve) or liganded (blue curve) forms of the protein. (C) Michaelis–Menten curve for hTDP2CAT using the fluorescence-based enzyme assay. Fifty picomoles of hTDP2CAT were incubated with substrate oligonucleotide for a period of 10 min, before the addition of Gyrasol reagents. Experimental data were fitted with a standard Michaelis–Menten equation (Prism 6, Graphpad software) in order to determine K_m and V_max parameters. Data points are the mean of three independent experiments, with error bars representing one S.D. (D) Dose–response curves for inhibition of hTDP2CAT by increasing concentrations of the indicated deazaflavin. See associated key for details, and IC50 values determined. Data points are the mean of six replicates, with error bars representing one S.D. (E) Molecular cartoon highlighting the binding position of 163, relative to the active site of hTDP2CAT. The compound packs against an extended hydrophobic shelf (light grey molecular surface + stick representation) formed by the side chains of Trp297, Thr305, Ile307, Leu313 and Phe315. The compound binds at a distance (> 9 Å) from the active site of the enzyme, as indicated by the side chains of Asp152 and Glu152, and the magnesium cofactor (purple sphere). (F) Top: representative image for the gel-based enzyme activity assay. hTDP2CAT efficiently catalyses the conversion of a 5'-phosphorylated (5'-Y) DNA duplex substrate to a 5'-phosphorylated product (5'-P) with time. Although 163 clearly inhibits the human enzyme, it is ineffective against the mouse equivalent. Bottom: quantification of gel-based assay. Data represent the mean of three independent experiments, with errors bars representing one S.D.
Conversely, mTDP2CAT, although crystallographically well-behaved and able to yield high-resolution structures, does not behave and able to yield high-resolution structures, does not

Clear difference electron density maps identified the binding site and general pose of this class of inhibitor bound to TDP2 (Supplementary Figure S2).

The experimentally determined binding-mode of 163 is surprisingly different from that predicted by molecular docking studies [13], in which the pyrimido-dione ring of the tricyclic core, was hypothesized to bind to the magnesium cofactor – required for catalytic activity of TDP2 – and made few (if any) hydrogen bonds directly to the protein.

Instead, our data indicate that the tricyclic deazaflavin core of 163 unexpectedly packs against an extended hydrophobic patch, formed by the side chains of Trp297, Thr299, Leu305, Ile307, Cys311, Leu313 and Phe315, which lies at the mouth of the channel leading to the active site, more than 9 Å from the catalytic Mg2+ ion bound by the carboxyl side chains of Asp122 and Glu152 (Figure 2E).

Due to the persistently poor crystallization behaviour of the human protein, and the need to characterize fully this unusual and unexpected binding mode of the deazaflavin inhibitor, we switched species and used the murine form of the enzyme (mTDP2CAT), which yielded well-behaved crystals diffracting to high-resolution; as in previous studies [24]. As a preliminary experiment, we tested the ability of 163 to inhibit mTDP2CAT in a gel-based assay. Unexpectedly, although 163 readily inhibited the catalytic activity of hTDP2CAT – preventing conversion of 5′-phosphotyrosyl termini to 5′-phosphates on a DNA duplex substrate – it failed to inhibit the mouse protein (Figure 2F).

Comparison of the mouse and human TDP2 amino acid sequences revealed substantial differences in a segment of polypeptide, denoted the ‘M7-motif’ [24], delimited by highly conserved ‘TWDT’ (amino acids 296–299 in humans) and ‘RFDR’ (amino acids 314–317) motifs. A multiple amino acid sequence alignment of this region (Figure 3A) shows it to be conserved in length (14 residues) among different organisms, but poorly conserved in amino acid sequence and somewhat variable in conformation (Figure 3B). Significantly, the M7-motif maps to the binding site we observe for 163 in hTDP2CAT, where human TDP2 residues Cys311 and Leu313, along with Ala309, coalesce to form a ‘hydrophobic-shelf’ on which the deazaflavin core of 163 sits. Replacement of Cys311 and Leu313 in hTDP2 with the equivalent residues Tyr321 and His323 in mTDP2 disrupts this hydrophobic-shelf and explains the resistance of the mouse enzyme to the deazaflavin-based inhibitors (Figure 3C).

**Development of a protein surrogate: m2hTDP2CAT**

Although hTDP2CAT is effectively inhibited by 163 and related deazaflavins, its poor crystallographic behaviour greatly limits the degree to which structure-led approaches can be used in order to optimize these compounds further for clinical development. Conversely, mTDP2CAT, although crystallographically well-behaved and able to yield high-resolution structures, does not

**Table 1 Data collection and refinement statistics**

*Values in parentheses are for highest-resolution shell. †Data isotropic to this resolution. §PDB entry used as ‘reference model’ during refinement.

| Data collection | hTDP2-CAT | hTDP2-CAT † + 163 | m2hTDP2-CAT † + 163 | m2hTDP2-CAT † + 148 |
|----------------|-----------|------------------|---------------------|---------------------|
| Space group    | P3_21     | P6_3 22          | P2_1                | P2_1                |
| Cell dimensions| a, b, c (Å) | 92.54, 92.54, 119.07 | 68.52, 68.52, 209.51 | 61.00, 42.80, 108.75 |
| R_work/R_free | 0.26/0.30 | 0.17/0.17        | 0.16/0.20           | 0.16/0.20           |
| Multiplicity   | 4.8 (4.9) | 6.3 (6.8)        | 2.9 (2.1)           | 3.1 (3.2)           |
| Completeness (%) | 92.4 (99.7) | 99.9 (100)        | 98.0 (79.7)         | 99.2 (98.9)         |
| Resolution (Å) | 47.79–3.10 | 45.22–3.40        | 42.8–1.80           | 42.07–1.70          |
| No. of atoms   | 3553      | 7545             | 112934              | 112934              |
| Protein        | 98.2      | 119.9            | 23.5                | 26.6                |
| Water          | 89.3      | 78.7             | 42.1                | 39.9                |
| Bond lengths (Å) | 0.002     | 0.001           | 0.008               | 0.020               |
| Bond angles (°) | 0.551     | 0.435           | 0.98                | 1.654               |
| Reference model| 4GYZ      | 4GYZ             | N/A                 | N/A                 |
| Ramachandran   | Outliers (%) | 5                | 0                   | 0                   |
|                | Favoured (%) | 92.4             | 97.9                | 97.9                |
|                | MolProbity score | 1.8              | 1.28                | 1.50                |

© 2016 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution Licence 4.0 (CC BY).
bind deazaflavin inhibitors due to sequence differences in the M7-motif.

To overcome these problems, we designed a series of mutations in the M7-motif and associated structure, designed to ‘humanize’ the inhibitor-binding site of mTDP2 while retaining the favourable murine surface that facilitates well-ordered crystals. Rather than exchange the entire mouse M7-motif for that of the human protein, we decided as an initial approach only to ‘humanize’ the amino acids expected to be in the proximity of the bound compound, and not those which would simply point towards solvent. We therefore created the expression construct m2hTDP2CAT (m2h = mouse–‘to’–human) by mutating the following mouse residues to their human equivalent: E242G, Q278R, Y321C and H323L.

The m2hTDP2CAT protein retained full phosphodiesterase activity, and consistent with our prediction that the resistance of the mouse protein to deazaflavins was due to the variant M7-motif, this activity in m2hTDP2CAT was inhibited by 163 (Figure 3D). As no further optimization of the ‘humanized’ construct was therefore required, m2hTDP2CAT was used for all subsequent structural analyses.

High-resolution co-crystal structure of m2hTDP2CAT bound to 163

We were able to validate our approach, by determining the X-ray crystal structure of m2hTDP2CAT bound to 163, at a resolution of 1.8 Å (Table 1). Superposition of the low-resolution hTDP2CAT and high-resolution m2hTDP2CAT structures in complex with 163, confirms that the binding site is conserved across both proteins (Supplementary Figure S3). However, the higher resolution data obtained with the m2hTDP2CAT surrogate, allows a far more detailed characterization of the interaction of the inhibitor with
the TDP2 catalytic domain (Figure 4A and Supplementary Figure S2).

The guanidinium head group of Arg^{276} (all numbering is for the mouse protein, the equivalent in human is calculated by subtraction of 10) is involved in an extensive hydrogen-bond network, including both carbonyl and nitrogen groups of the 163 pyrimido-dione ring, as well as the backbone carbonyl and side chain (via a water molecule) of Asp^{277}. As in the fully human protein, amino acids of the M7-motif coalesce to form the ‘hydrophobic-shelf’, which permits extensive van der Waals interactions with the tricyclic deazaflavin core; these residues include Trp^{307}, Ile^{317}, Ala^{319}, Cys^{321} (text in italics represent a ‘humanized’ amino acid residue), Leu^{323} and Phe^{325} (Figure 3A). The tetrazole R₁ substituent of 163, is directed towards solvent, but packs against the carbon-atoms of the Arg^{241} side chain, providing additional van der Waals interactions.

High-resolution co-crystal structure of m2hTDP2^{CAT} bound to 148

Raof et al. [13] also described and characterized two hydroxyphenyl substituents at the R₁ position of the deazaflavin core, in combination with the cyano group at the R₃ position; compound 147 (3-hydroxyphenol) and 148 (4-hydroxyphenol) with reported EC₅₀ values of 50 nM and 90 nM respectively (Figure 2A). We were successful in obtaining diffracting crystals of 148 in complex with m2hTDP2^{CAT}, determining the structure at a resolution of 1.7 Å (Table 1). In this instance, we also supplemented the purification buffers with manganese chloride (iso-structural with magnesium, but readily discernible in electron density maps) in order to more fully define any interaction of the inhibitors with the metal-dependent catalytic centre of the enzyme.

In the 148 complex, the side chains of Arg^{276} and Asp^{277} make the same set of interactions with the carbonyl and nitrogen groups of the pyrimido-dione ring, as with 163. However, the side chain of Arg^{241} occupies a different position, breaking its hydrogen bond interaction with Asp^{277}, and instead packing in a π–π interaction against the face of the tricyclic core of the deazaflavin (Figure 4B and Supplementary Figure S2). Interestingly, the p-hydroxyl group of the R₁ substituent in 148, points directly towards the catalytic core of the protein and makes a series of water-mediated contacts to the side chains of Asp^{277} and Asp^{272}. Electron density maps also clearly showed the position...
Mode of action of DNA-competitive small molecule inhibitors of TDP2

Several structures for the catalytic domain of TDP2 in complex with nucleic acid have been reported [24,25]. However, there is disagreement between these structures regarding the path that the bound DNA follows across the protein surface; potentially as a result of the different substrates used (double compared with single-stranded) or possibly due to different crystal packing interactions.

However, taking PDB entries 4GZ1 and 4F1H as representative examples of the two different modes of TDP2–product DNA interaction, we note that although the DNA trajectories are different (Figure 5A), the position of the first (Nuc1) and second nucleotides (Nuc2) of the previously modified strand are highly similar in both structures (Figure 5B).

Regardless of which of these TDP2–product DNA structures actually represents a physiologically relevant binding mode, comparison with the structures reported here shows that the deazaflavins occupy a position equivalent to that of Nuc2, with the pendant group sitting at the position of the 5′-phosphate, and the deazaflavin core at those of the ribose and base moieties.

**Figure 5  Deazaflavin binding relative to bound DNA**

(A) The deazaflavin-scaffold interacts with the ‘hydrophobic shelf’ formed by residues of the M7-motif. Molecular surface representations for: (left) m2hTDP2CAT in complex with 163; (middle) mouse TDP2CAT in complex with a double-stranded product DNA (PDB: 4GZ1); (right) zebrafish TDP2CAT in complex with a single-stranded product DNA (PDB: 4F1H). (B) Superposition of structures reveals that the first two nucleotides of either product DNA (Nuc1, Nuc2) occupy highly similar positions when bound to TDP2. The deazaflavins occupy a position equivalent to Nuc2, with the pendant group sitting at the position of the 5′-phosphate, and the deazaflavin core at those of the ribose and base moieties. In both panels, the carbons of the previously modified 5′ nucleotide are coloured yellow, and those of the deazaflavin 163 in green.

**DISCUSSION**

The proteins that constitute the DNA damage response (DDR) are increasingly being recognized as attractive targets for the development of new drugs, which exploit the inherent genomic

© 2016 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution Licence 4.0 (CC BY).
instability found in many cancers [27,28]. This field has been galvanized by the approval of olaparib as a monotherapy for the treatment of specific subsets of patients with advanced ovarian cancer. Olaparib is an inhibitor of the DNA damage sensor poly(ADP-ribose) polymerase 1 (PARP1), which exploits cancer-associated genetic defects in one DNA repair system (homologous recombination-mediated DSB repair) by inhibiting a second system (single-strand break repair) to achieve potent and selective ‘synthetic lethality’ against tumour cells [29].

DDR enzymes that utilize cofactors – such as PARPs or protein kinases for example – fall within the traditional canon of drug development targets; i.e. where a specific cofactor-competitive inhibitor can be readily found. However, many biologically interesting DNA repair ‘targets’ for cancer drug discovery lack such cofactors and instead act directly on DNA. These present the challenge of discovering compounds capable of out-competing an often substantial protein–DNA interaction potentially dominated by highly polar interactions with the negatively-charged sugar-phosphate backbone.

The discovery of deazaflavins as TDP2 inhibitors [13] highlighted the possibility that uncharged and ‘drug-like’ competitive inhibitors of DNA binding to a DNA repair enzyme, could be found and developed. However, the mode of action of these was unclear, and limited further optimization of these compounds could be found and developed. However, the mode of action of these was unclear, and limited further optimization of these compounds could be found and developed. However, the mode of action of these was unclear, and limited further optimization of these compounds could be found and developed.

It is worth noting here (as previously reported [13]) that deazaflavin-based compounds are, in themselves, highly unlikely to be suitable as anticancer agents; in most part due to the general inability of the chemical scaffold to penetrate the cell membrane of mammalian cells. However, with the data gleaned from the high-resolution crystal structures presented here, we now have a detailed understanding of their mode of action, which will in turn, inform the discovery and development of alternative scaffolds, and may eventually lead to the conversion of this highly useful ‘tool compound’ into a potential bona fide drug candidate for the treatment of disease.

ACCESSION NUMBERS

5J3P, 5J3S, 5J3Z and 5J42 for apo-hTDP2CAT, hTDP2CAT + 163, m2hTDP2CAT + 163 and m2hTDP2CAT + 148 respectively.

REFERENCES

1 Pype, S., Declercq, W., Ibrahim, A., Michiels, C., Van Rietschoten, J.G., Dewulf, N., de Boer, M., Vandenabeele, P., Huytebroeck, D. and Remacle, J.E. (2000) TRAP a novel protein that associates with CD40, tumor necrosis factor (TNF) receptor-75 and TNF receptor-associated factors (TRAFs), and that inhibits nuclear factor-kappa B activation. J. Biol. Chem. 275, 16586–16592 CrossRef PubMed

2 Pei, H., Yardy, J.S., Leng, Q., Zhao, Q., Watson, D.K. and Li, R. (2003) EAP1 interacts with ETS1 and modulates its transcriptional function. Oncogene 22, 2699–2709 CrossRef PubMed

3 Cortes-Ledesma, F., El Khami, S.F., Zuma, M.C., Otsb, K. and Caldecott, K.W. (2009) A human 5′-tyrosyl DNA phosphodiesterase that repairs topoisomerase-mediated DNA damage. Nature 461, 674–678 CrossRef PubMed

4 Zeng, Z., Cortes-Ledesma, F., El Khami, S.F. and Caldecott, K.W. (2011) TDP2/TRAP is the major 5′-DNA phosphodiesterase activity in vertebrate cells and is critical for cellular resistance to topoisomerase II-induced DNA damage. J. Biol. Chem. 286, 403–409 CrossRef PubMed

5 Virgen-Slane, R., Rozovics, J.M., Fitzgerald, K.D., Ngo, T., Chou, W., van der Heden van Noort, F., Filipov, D.V., Gershon, P.D. and Semler, B.L. (2012) An RNA virus hijacks an incognito function of a DNA repair enzyme. Proc. Natl. Acad. Sci. U.S.A. 109, 14634–14639 CrossRef PubMed

6 Nitiss, J.L. (2009) DNA topoisomerase II and its growing repertoire of biological functions. Nat. Rev. Cancer 9, 327–337 CrossRef PubMed

7 Frederick, C.A., Williams, L.D., Ughetto, G., van der Marel, G.A., van Boom, J.H., Rich, A. and Wang, A.H. (1990) Structural comparison of anticancer drug-DNA complexes: adriamycin and daunomycin. Biochemistry 29, 3538–3549 CrossRef PubMed

8 Wu, C.C., Li, Y.C., Wang, Y.R., Li, T.K. and Chan, N.L. (2013) On the structural basis and design guidelines for type II topoisomerase-targeting anticancer drugs. Nucleic Acids Res. 41, 10630–10640 CrossRef PubMed

9 Pomnier, Y., Luo, E., Zhang, H. and Marchand, C. (2010) DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. Chem. Biol. 17, 421–433 CrossRef PubMed

10 Blum, R.H. and Carter, S.K. (1974) Adriamycin. A new anticancer drug with significant clinical activity. Am. Intern. Med. 80, 249–259 CrossRef PubMed

11 Kubuschok, B., Heid, G. and Pfreundschuh, M. (2010) Management of diffuse large B-cell lymphoma (DLBCL). Cancer Treat. Res. 155, 271–286 CrossRef PubMed

12 Nitiss, J.L. (2009) Targeting DNA topoisomerase II in cancer chemotherapy. Nat. Rev. Cancer 9, 338–350 CrossRef PubMed

13 Raaf, A., Depledge, P., Hamilton, N.M., Hamilton, N.S., Hitchin, J.R., Hopkins, G.V., Jordan, A.M., Maguire, L.A., Mould, D.P. et al. (2013) Topoisomerase and deazaflavin as the first reported selective small molecule inhibitors of tyrosyl-DNA phosphodiesterase II. J. Med. Chem. 56, 6352–6370 CrossRef PubMed

14 Walker, S., Meinberg, C., Gibby, R.A., Askwith, T., Williams, G., Rimmelsland, F.H., Pearl, L.H., Oliver, A.W., El-Khamsy, S., Ward, S. and Addy, J.R. (2014) Development of an oligonucleotide-based fluorescence assay for the identification of tyrosyl-DNA phosphodiesterase 1 (TDP1) inhibitors. Anal. Biochem. 454, 17–22 CrossRef PubMed

15 Kabisch, W. (2010) XDS. Acta Crystallogr. D Biol. Crystallogr. 66, 125–132 CrossRef PubMed

AUTHOR CONTRIBUTION

Peter Hornyak, Trevor Askwith, Sarah Walker, Emilka Komulainen, Michael Paradowski, Lewis Pennicott, Edward Bartlett, Nigel Brissett, Ali Raof, Mandy Watson and Allan Jordan performed experiments and analysed results. Peter Hornyak additionally cloned, overexpressed and purified proteins, setup crystallization trials, and solved the structures. Antony Oliver refined and deposited the final models. Donald Ogilvie, Simon Ward and John Atack analysed and discussed the data. Laurence Pearl, Keith Caldecott and Antony Oliver conceived the study, designed experiments, and wrote the manuscript.

ACKNOWLEDGEMENTS

We thank Mark Roe for assistance with X-ray diffraction data collection. We also thank Diamond Light Source, Didcot, for access to synchrotron radiation.

FUNDING

This work was supported by the Cancer Research U.K. Programme [grant numbers C302/A14532 (to L.H.P. and A.W.O.), D5653/A16771 (to K.W.C.) and C480/A11411 (to D.J.O.)].
Mode of action of DNA-competitive small molecule inhibitors of TDP2

16 Evans, P. (2006) Scaling and assessment of data quality. Acta Crystallogr. D Biol. Crystallogr. 62, 72–82 CrossRef PubMed
17 Evans, P.R. (2011) An introduction to data reduction: space-group determination, scaling and intensity statistics. Acta Crystallogr. D Biol. Crystallogr. 67, 262–292 CrossRef PubMed
18 Evans, P.R. and Murshudov, G.N. (2013) How good are my data and what is the resolution? Acta Crystallogr. D Biol. Crystallogr. 69, 1204–1214 CrossRef PubMed
19 Winn, M.D., Ballard, C.C., Cowtan, K.D., Dodson, E.J., Emsley, P., Evans, P.R., Keegan, R.M., Krissinel, E.B., Leslie, A.G., McCoy, A. et al. (2011) Overview of the CCP4 suite and current developments. Acta Crystallogr. D Biol. Crystallogr. 67, 235–242 CrossRef PubMed
20 McCoy, A.J., Grosse-Kunstleve, R.W., Adams, P.D., Winn, M.D., Storoni, L.C. and Read, R.J. (2007) Phaser crystallographic software. J. Appl. Crystallogr. 40, 658–674 CrossRef PubMed
21 Emsley, P. and Cowtan, K. (2004) Coot: model-building tools for molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 60, 2126–2132 CrossRef PubMed
22 Adams, P.D., Afonine, P.V., Bunkoczi, G., Chen, V.B., Davis, I.W., Echols, N., Headd, J.J., Hung, L.W., Kapral, G.J., Grosse-Kunstleve, R.W. et al. (2010) PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D Biol. Crystallogr. 66, 213–221 CrossRef PubMed
23 Bricogne, G., Blanc, E., Brändli, M., Flensburg, C., Keller, P.W.P., Roversi, P., Shattil, A., Smart, O.S., Vonrhein, C. and Womack, T.O. (2015) BUSTER, version 2.10.2. ed., Global Phasing Ltd., Cambridge, U.K.
24 Schellenberg, M.J., Appel, C.D., Adhikari, S., Robertson, P.D., Ramsden, D.A. and Williams, R.S. (2012) Mechanism of repair of 5'–topoisomerase II-DNA adducts by mammalian tyrosyl-DNA phosphodiesterase 2. Nat. Struct. Mol. Biol. 19, 1363–1371 CrossRef PubMed
25 Shi, K., Kurashiki, K., Gao, R., Tsutakawa, S.E., Tainer, J.A., Pommier, Y. and Althara, H. (2012) Structural basis for recognition of 5'-phosphotyrosine adducts by Tdp2. Nat. Struct. Mol. Biol. 19, 1372–1377 CrossRef PubMed
26 Niesen, F.H., Berglund, H. and Vedadi, M. (2007) The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability. Nat. Protoc. 2, 2212–2221 CrossRef PubMed
27 O'Connor, M.J. (2015) Targeting the DNA damage response in cancer. Mol. Cell 60, 547–560 CrossRef PubMed
28 Pearl, L.H., Schierz, A.C., Ward, S.E., Al-Lazikani, B. and Pearl, F.M. (2015) Therapeutic opportunities within the DNA damage response. Nat. Rev. Cancer 15, 166–180 CrossRef PubMed
29 Lord, C.J., Tutt, A.N. and Ashworth, A. (2015) Synthetic lethality and cancer therapy: lessons learned from the development of PARP inhibitors. Annu. Rev. Med. 66, 405–470 CrossRef PubMed
30 Ali, A.A., Timinszky, G., Arribas-Bosacoma, R., Koziolowski, M., Hassa, P.O., Hassler, M., Ladurner, A.G., Pearl, L.H. and Oliver, A.W. (2012) The zinc-finger domains of PARP1 cooperate to recognize DNA strand breaks. Nat. Struct. Mol. Biol. 19, 685–692 CrossRef PubMed
31 Garcia, F., Pearl, L.H. and Oliver, A.W. (2011) The structural basis for substrate recognition by mammalian polynucleotide kinase 3' phosphatase. Mol. Cell 44, 385–396 CrossRef PubMed
32 Tsutakawa, S.E., Classen, S., Chapados, B.R., Arvai, A.S., Finger, L.D., Guenther, G., Tomlinson, C.G., Thompson, P., Sarker, A.H., Shen, B. et al. (2011) Human flap endonuclease structures, DNA double-base flipping, and a unified understanding of the FEN1 superfamily. Cell 145, 198–211 CrossRef PubMed
33 Maciejewski, S., Nguyen, J.H., Gomez-Herreros, F., Cortes-Ledesma, F., Caldecott, K.W. and Semler, B.L. (2015) Divergent requirement for a DNA repair enzyme during enterovirus infections. MBio. 7, e01931–e02015 PubMed

Received 2 March 2016/19 April 2016; accepted 19 April 2016
Accepted Manuscript online 20 April 2016, doi:10.1042/BCJ20160180

© 2016 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution Licence 4.0 (CC BY).